Literature DB >> 22355037

Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.

Prediman K Shah.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22355037      PMCID： PMC3345561          DOI： 10.1093/eurheartj/ehs040

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  19 in total

1.  High-density lipoprotein restores endothelial function in hypercholesterolemic men.

Authors:  Lukas E Spieker; Isabella Sudano; David Hürlimann; Peter G Lerch; Markus G Lang; Christian Binggeli; Roberto Corti; Frank Ruschitzka; Thomas F Lüscher; Georg Noll
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

2.  Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

Authors:  Thomas F Lüscher; Stefano Taddei; Juan-Carlos Kaski; J Wouter Jukema; David Kallend; Thomas Münzel; John J P Kastelein; John E Deanfield
Journal:  Eur Heart J       Date:  2012-02-16       Impact factor: 29.983

3.  Torcetrapib impairs endothelial function in hypertension.

Authors:  Branko Simic; Matthias Hermann; Sidney G Shaw; Laurent Bigler; Urs Stalder; Carola Dörries; Christian Besler; Thomas F Lüscher; Frank Ruschitzka
Journal:  Eur Heart J       Date:  2011-09-14       Impact factor: 29.983

Review 4.  Progress in HDL-based therapies for atherosclerosis.

Authors:  Kuang-Yuh Chyu; Anish Peter; Prediman K Shah
Journal:  Curr Atheroscler Rep       Date:  2011-10       Impact factor: 5.113

Review 5.  Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.

Authors:  Cesare R Sirtori
Journal:  Expert Opin Investig Drugs       Date:  2011-10-01       Impact factor: 6.206

Review 6.  New horizons for cholesterol ester transfer protein inhibitors.

Authors:  Gregory G Schwartz
Journal:  Curr Atheroscler Rep       Date:  2012-02       Impact factor: 5.113

7.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

8.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

Authors:  Michiel L Bots; Frank L Visseren; Gregory W Evans; Ward A Riley; James H Revkin; Charles H Tegeler; Charles L Shear; William T Duggan; Ralph M Vicari; Diederick E Grobbee; John J Kastelein
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

9.  Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP.

Authors:  Patrícia M Cazita; Denise F Barbeiro; Ana I S Moretti; Eder C R Quintão; Francisco G Soriano
Journal:  Shock       Date:  2008-11       Impact factor: 3.454

10.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

Authors:  Zahi A Fayad; Venkatesh Mani; Mark Woodward; David Kallend; Markus Abt; Tracy Burgess; Valentin Fuster; Christie M Ballantyne; Evan A Stein; Jean-Claude Tardif; James H F Rudd; Michael E Farkouh; Ahmed Tawakol
Journal:  Lancet       Date:  2011-09-09       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.